Fanregratinib tartrate

酒石酸凡瑞格拉替尼

Report date: 2025/12/29 09:31:53
NME

Base Information

Drug NameFanregratinib tartrate
Drug Alias NameHMPL-453 tartrateFanregratinibHMPL-453
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionFibroblast growth factor receptor 3 antagonistsFibroblast growth factor receptor 1 antagonistsFibroblast growth factor receptor 2 antagonists +[4] 
TargetsFibroblast growth factor receptor 1Fibroblast growth factor receptor 3Fibroblast growth factor receptor 2
Therapy Area/IndicationsSolid tumoursBiliary Tract NeoplasmsNeoplasms, Mesothelial +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryAustraliaMainland China
CombinationsNo
Global Highest StatusNDA/BLA
Highest Status in ChinaNDA/BLA
Originator CompaniesHutchison Medipharma Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesHutchmed (Hong Kong) LtdHutchison Medipharma Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursBiliary Tract NeoplasmsCholangiocarcinoma
Inactive IndicationsNeoplasms, MesothelialMesothelioma

Other Information

ATC CodeN/A
Related LinksN/A